{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:17:40Z","timestamp":1787944660642,"version":"build-2784847793"},"reference-count":76,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Carboplatin, a second-generation platinum-based therapy, is widely indicated for first-line treatment of selected solid tumors. Furthermore, it represents a well-established alternative to cisplatin in populations characterized by chronic kidney disease (CKD) or clinical frailty. The renal profile of carboplatin toxicity is most commonly linked to hypomagnesemia, and less frequently to acute kidney injury (AKI) or a persistent decline in GFR. While hypomagnesemia is the most frequent renal adverse effect, severe episodes that impact anticancer treatment are uncommon. Reductions in GFR carry significant clinical implications because they directly affect carboplatin dosing and drive cumulative hematologic toxicity that leads to adverse clinical events, which may be more relevant in older and sarcopenic patients. Carboplatin toxicity is highly dependent on systemic exposure and is quantified by the area under the concentration\u2013time curve (AUC). Inaccurate estimation of GFR, particularly when using the Cockcroft\u2013Gault (CG) equation, frequently leads to GFR overestimation and carboplatin overdose. Thus, precise dose adjustment according to GFR is of the utmost importance. In this review, we examine the renal complications associated with carboplatin, including the reported incidence and clinical patterns of kidney injury, with particular emphasis on dose-adjustment strategies based on GFR, encompassing patients with CKD and those receiving dialysis, as well as practical considerations for the prevention and management of carboplatin nephrotoxicity.<\/jats:p>","DOI":"10.3390\/cancers18172801","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:33:52Z","timestamp":1787942032000},"page":"2801","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevention and Management of Carboplatin Nephrotoxicity"],"prefix":"10.3390","volume":"18","author":[{"given":"Renato A.","family":"Caires","sequence":"first","affiliation":[{"name":"Sao Paulo State Cancer Institute, Division of Nephrology, University of Sao Paulo School of Medicine, Sao Paulo 01246-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elerson C.","family":"Costalonga","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Renal Vida Association, Blumenau 89010-500, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f4nica Torres","family":"Costa e Silva","sequence":"additional","affiliation":[{"name":"Sao Paulo State Cancer Institute, Division of Nephrology, University of Sao Paulo School of Medicine, Sao Paulo 01246-000, Brazil"},{"name":"Laborat\u00f3rio de Investiga\u00e7\u00e3o M\u00e9dica (LIM-16), Division of Nephrology, University of Sao Paulo School of Medicine, Sao Paulo 01246-903, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/ndt\/gfaf251","article-title":"Nephrotoxicity of conventional chemotherapeutics: Part 1\u2014Platinum compounds and antimetabolite agents","volume":"41","author":"Kelly","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s12032-025-02812-3","article-title":"Advances in platinum-based cancer therapy: Overcoming platinum resistance through rational combinatorial strategies","volume":"42","author":"Yusoh","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.ackd.2021.08.001","article-title":"Conventional Chemotherapy Nephrotoxicity","volume":"28","author":"Gupta","year":"2021","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/ajco.13481","article-title":"Carboplatin and hypomagnesemia: Is it really a problem?","volume":"17","author":"Gaughran","year":"2021","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejca.2019.08.033","article-title":"Vinflunine\/gemcitabine versus carboplatin\/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)","volume":"127","author":"Holmsten","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wang, L., Yang, K., Zhao, H., Lv, P., Cai, C., Wang, Z., and Wang, B. (2025). Real-world safety of carboplatin in non-small cell lung cancer: A retrospective signal detection and subgroup analysis based on the FAERS database. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1590738"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized Phase II\/III Trial Assessing Gemcitabine\/Carboplatin and Methotrexate\/Carboplatin\/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00280-017-3326-5","article-title":"Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity","volume":"80","author":"Bretagne","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Car-boplatin dosage: Prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.6004\/jnccn.2025.7048","article-title":"Sarcopenia, Elevated Body Mass Index, and Platinum-Associated Adverse Events in Patients With Lung Cancer","volume":"23","author":"Lyu","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.bcp.2010.11.016","article-title":"Organic cation transporter OCT\/SLC22A and H+\/organic cation antiporter MATE\/SLC47A are key molecules for nephrotoxicity of platinum agents","volume":"81","author":"Yonezawa","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/CAD.0b013e3283650bda","article-title":"Platinum compounds in children with cancer: Toxicity and clinical management","volume":"24","author":"Ruggiero","year":"2013","journal-title":"Anticancer Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5114\/wo.2011.21810","article-title":"Nephrotoxicity of platinum derivatives in children\u2014A review of the literature","volume":"2","author":"Stefanowicz","year":"2011","journal-title":"Wspolczesna Onkol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0002-9343(91)80022-E","article-title":"Acute renal failure associated with the use of intraperitoneal carboplatin: A report of two cases and review of the literature","volume":"90","author":"McDonald","year":"1991","journal-title":"Am. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kuroda, K. (2016). Role of oxidative stress in drug-induced kidney injury. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17111826"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.abb.2009.06.007","article-title":"Carboplatin-induced alteration of the thiol homeostasis in the isolated perfused rat kidney","volume":"488","author":"Giustarini","year":"2009","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1523-1755.2004.00720.x","article-title":"Nephrotoxicity of platinum complexes is related to basolateral organic cation transport","volume":"66","author":"Ludwig","year":"2004","journal-title":"Kidney Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.bbamcr.2014.12.033","article-title":"Platinum-induced kidney damage: Unraveling the DNA damage response (DDR) of renal tubular epithelial and glomerular endothelial cells following platinum injury","volume":"1853","author":"Thomale","year":"2015","journal-title":"Biochim. Biophys. Acta (BBA) \u2014Mol. Cell Res."},{"key":"ref_19","first-page":"1","article-title":"Nitric oxide signaling in inflammation and oxidative stress: Mechanistic insights and therapeutic opportunities","volume":"1","author":"Yaghoubi","year":"2026","journal-title":"Nexus Pathophysiol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10157-024-02490-x","article-title":"An integrated view of cisplatin-induced nephrotoxicity, hepatotoxicity, and cardiotoxicity: Characteristics, common molecular mechanisms, and current clinical management","volume":"28","author":"Oliveira","year":"2024","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"21574","DOI":"10.1038\/s41598-021-00955-7","article-title":"The chemotherapeutic drug carboplatin affects macrophage responses to LPS and LPS tolerance via epigenetic modifications","volume":"11","author":"Boonmee","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0305-7372(85)90014-3","article-title":"Preclinical antitumor and toxicologic profile of carboplatin","volume":"12","author":"Rose","year":"1985","journal-title":"Cancer Treat. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/08860220701643591","article-title":"End-Stage Renal Disease Following Carboplatin Chemotherapy for a Nasopharyngeal Carcinoma","volume":"29","author":"Tarrass","year":"2007","journal-title":"Ren. Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000542906","article-title":"Severe Hypomagnesemia in a Patient Treated Using Carboplatin Co-Administered with Vonoprazan","volume":"18","author":"Taniguchi","year":"2025","journal-title":"Case Rep. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.bbadis.2007.03.009","article-title":"TRPM6 and TRPM7\u2014Gatekeepers of human magnesium metabolism","volume":"1772","author":"Schlingmann","year":"2007","journal-title":"Biochim. Biophys. Acta (BBA) -Mol. Basis Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1016\/j.ekir.2025.08.012","article-title":"Dapagliflozin-Associated Resolution of Acute Carboplatin-Induced Hypomagnesemia\u2014Exploration of TRPM6\/7 Channel Activity","volume":"10","author":"Shah","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.bjc.6690697","article-title":"Dose-related nephrotoxicity of carboplatin in children","volume":"81","author":"English","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Trevisani, F., Di Marco, F., Floris, M., Pani, A., Minnei, R., Scartozzi, M., Cirillo, A., Gelibter, A., Botticelli, A., and Rijavec, E. (2022). Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario. Vaccines, 10.","DOI":"10.3390\/vaccines10050679"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/bjc.1991.34","article-title":"Carboplatin and renal function in children","volume":"63","author":"Stevens","year":"1991","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1002\/hsr2.479","article-title":"The influence of acute kidney disease on the clinical outcomes of patients who received cisplatin, carboplatin, and oxaliplatin","volume":"5","author":"Fernandes","year":"2022","journal-title":"Heal. Sci. Rep."},{"key":"ref_31","unstructured":"(2026, August 24). Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury and Acute Kidney Disease Work Group. KDIGO 2026 Clinical Practice Guideline for Acute Kidney Injury and Acute Kidney Disease. Public Review Draft. Available online: https:\/\/kdigo.org\/guidelines\/acute-kidney-injury\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.aicoj.2025.100017","article-title":"What new renal biomarkers tell us about renal physiology","volume":"16","author":"Joannidis","year":"2026","journal-title":"Ann. Intensive Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7314\/APJCP.2015.16.2.407","article-title":"Predictive Role of Neutrophil Gelatinase-Associated Lipocalin in Early Diagnosis of Platin-Induced Renal Injury","volume":"16","author":"Seker","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dimov, N., Yaneva, A., Valcheva, E., Raycheva, G., Popov, V., Delipavlova, R., Nikolov, D., and Grudeva-Popova, Z. (2025). Biomarkers for Early Detection of Cisplatin-Induced Nephrotoxicity. Life, 15.","DOI":"10.3390\/life15091432"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/IJNRD.S135271","article-title":"Urinary TIMP2\u00b7IGFBP7 for the prediction of platinum-induced acute renal injury","volume":"10","author":"Schanz","year":"2017","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1634\/theoncologist.2018-0465","article-title":"Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin","volume":"24","author":"Liu","year":"2019","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.34067\/KID.0000000000000349","article-title":"Carboplatin Dosing on the Basis of Renal Function: 30+ Years after Calvert","volume":"5","author":"Schwenk","year":"2024","journal-title":"Kidney360"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1078155220978446","article-title":"Accurate determination of glomerular filtration rate in adults for carboplatin dosing: Moving beyond Cockcroft and Gault","volume":"27","author":"Tsang","year":"2020","journal-title":"J. Oncol. Pharm. Pr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/IGC.0b013e31822127ad","article-title":"Carboplatin dosing in ovarian cancer: Problems and pitfalls","volume":"21","author":"Collins","year":"2011","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/jnci\/92.17.1434","article-title":"Calvert\u2019s Formula for Dosing Carboplatin: Overview and Concerns of Applicability in High-Dose Setting","volume":"92","author":"Mazumdar","year":"2000","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0959-8049(99)00266-X","article-title":"A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage","volume":"36","author":"Chatelut","year":"2000","journal-title":"Eur. J. Cancer."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00280-019-04020-z","article-title":"Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance","volume":"85","author":"Paludetto","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/1078-0432.CCR-20-3201","article-title":"CamGFR v2: A new model for estimating the glomerular filtration rate from standardized or non-standardized creatinine in patients with cancer","volume":"27","author":"Williams","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2017.72.7578","article-title":"New model for estimating glomerular filtration rate in patients with cancer","volume":"35","author":"Janowitz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41416-025-03190-3","article-title":"Accuracy of glomerular filtration rate estimates among patients with cancer","volume":"133","author":"Lees","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"gfaf116.0535","DOI":"10.1093\/ndt\/gfaf116.0535","article-title":"#1061 Re-defining carboplatin dosage using eGFR-CR-CYS compared to Cockcroft Gault and impact on platinum-associated adverse events","volume":"40","author":"Khor","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_47","first-page":"261","article-title":"Impact of Computed Tomography\u2013Derived Body Composition Analysis on the Performance of GFR Estimating Equations in Patients with Cancer","volume":"21","author":"Sise","year":"2025","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"(2024). Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"103161","DOI":"10.1016\/j.eclinm.2025.103161","article-title":"Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice","volume":"82","author":"Sandhu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: Known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"861","DOI":"10.34067\/KID.0000000736","article-title":"Update on the Assessment of GFR in Patients with Cancer","volume":"6","author":"Xiong","year":"2025","journal-title":"Kidney360"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","article-title":"Assessment of GFR in patients with cancer: A statement from the American Society of Onco-Nephrology","volume":"19","author":"Kitchlu","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.kint.2021.12.010","article-title":"A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors","volume":"101","author":"Gil","year":"2022","journal-title":"Kidney Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2165\/00003088-199121040-00002","article-title":"Clinical pharmacokinetics of carboplatin","volume":"21","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/annonc\/mdp598","article-title":"Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients","volume":"21","author":"Janus","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_56","first-page":"157","article-title":"Pharmacokinetics of Carboplatin in a Patient Suffering from Advanced Ovarian Carcinoma with Hemodialysis-Dependent Renal Insufficiency","volume":"66","author":"Chatelut","year":"1994","journal-title":"Nephron"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s13691-023-00640-8","article-title":"Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: A case report and literature review","volume":"13","author":"Ushijima","year":"2023","journal-title":"Int. Cancer Conf. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s12032-014-0848-0","article-title":"Dose adjustment of carboplatin in patients on hemodialysis","volume":"31","author":"Guddati","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0272-6386(83)80060-2","article-title":"Drug Prescribing in Renal Failure: Dosing Guidelines for Adults","volume":"3","author":"Bennett","year":"1983","journal-title":"Am. J. Kidney Dis."},{"key":"ref_60","first-page":"1","article-title":"Targeting inflammatory pathways: Are we entering a new era of mechanism-driven therapeutics?","volume":"1","author":"Kordkatouli","year":"2026","journal-title":"Nexus Pathophysiol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.34067\/KID.0005622020","article-title":"Hypomagnesemia in the cancer patient","volume":"2","author":"Workeneh","year":"2021","journal-title":"Kidney360"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.0000000700","article-title":"SGLT2 Inhibitors Blunt Kidney Magnesium Wasting in Acute Cisplatin-Induced Hypomagnesemia with Effects on the Thick Ascending Limb and Distal Convoluted Tubule","volume":"36","author":"Jesus","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"100697","DOI":"10.1016\/j.xkme.2023.100697","article-title":"SGLT2 Inhibitors in Management of Severe Hypomagnesemia in Patients Without Diabetes: A Report of 4 Cases","volume":"5","author":"Shah","year":"2023","journal-title":"Kidney Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7244013","DOI":"10.1155\/ah\/7244013","article-title":"SGLT2 Inhibitor\u2013Associated Euglycemic Diabetic Ketoacidosis (EDKA) in Hematologic Malignancy Patients: A Case Series","volume":"2025","author":"Artz","year":"2025","journal-title":"Adv. Hematol."},{"key":"ref_65","first-page":"7437892","article-title":"Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin","volume":"2020","author":"Sexe","year":"2020","journal-title":"Case Rep. Crit. Care"},{"key":"ref_66","first-page":"3901741","article-title":"Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy","volume":"2019","author":"Papadokostaki","year":"2019","journal-title":"Case Rep. Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/jamaoncol.2025.0756","article-title":"Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury","volume":"11","author":"Gupta","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin","volume":"17","author":"Go","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41581-022-00631-7","article-title":"Cisplatin nephrotoxicity: New insights and therapeutic implications","volume":"19","author":"Tang","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e2237699","DOI":"10.1001\/jamanetworkopen.2022.37699","article-title":"Comparison of Carboplatin with Cisplatin in Small Cell Lung Cancer in US Veterans","volume":"5","author":"Azar","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2340\/1651-226X.2024.23960","article-title":"Reducing renal function assessment prior to platinum-based chemotherapy: A real-world evaluation","volume":"63","author":"Labots","year":"2024","journal-title":"Acta Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/ctrv.1999.0097","article-title":"Cisplatin and hypomagnesemia","volume":"25","author":"Lajer","year":"1999","journal-title":"Cancer Treat. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity: A review of the literature","volume":"31","author":"Manohar","year":"2017","journal-title":"J. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s13730-019-00437-w","article-title":"Carboplatin-related acute interstitial nephritis in a patient with pancreatic neuroendocrine tumor","volume":"9","author":"Asai","year":"2019","journal-title":"CEN Case Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-dose Carboplatin\/Etoposide\/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma","volume":"53","author":"Jodele","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ndt\/gfae233","article-title":"Effect of mannitol on cisplatin-associated acute kidney injury: A target trial emulation","volume":"40","author":"Gupta","year":"2024","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2801\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:38:55Z","timestamp":1787942335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":76,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172801"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172801","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}